ATE445404T1 - Verwendung von adefovir oder tenofovir zur hemmung von mmtv-artigen viren im zusammenhang mit brustkrebs und primärer biliärer zirrhose - Google Patents

Verwendung von adefovir oder tenofovir zur hemmung von mmtv-artigen viren im zusammenhang mit brustkrebs und primärer biliärer zirrhose

Info

Publication number
ATE445404T1
ATE445404T1 AT05706024T AT05706024T ATE445404T1 AT E445404 T1 ATE445404 T1 AT E445404T1 AT 05706024 T AT05706024 T AT 05706024T AT 05706024 T AT05706024 T AT 05706024T AT E445404 T1 ATE445404 T1 AT E445404T1
Authority
AT
Austria
Prior art keywords
adefovir
tenofovir
mmtv
breast cancer
inhibit
Prior art date
Application number
AT05706024T
Other languages
German (de)
English (en)
Inventor
Tomas Cihlar
Janet Douglas
Craig Gibbs
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Application granted granted Critical
Publication of ATE445404T1 publication Critical patent/ATE445404T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
AT05706024T 2004-01-21 2005-01-21 Verwendung von adefovir oder tenofovir zur hemmung von mmtv-artigen viren im zusammenhang mit brustkrebs und primärer biliärer zirrhose ATE445404T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53806604P 2004-01-21 2004-01-21
PCT/US2005/002043 WO2005072748A1 (en) 2004-01-21 2005-01-21 Use of adefovir or tenofovir for inhibiting mmtv-like viruses involved in breast cancer and primary biliary cirrhosis

Publications (1)

Publication Number Publication Date
ATE445404T1 true ATE445404T1 (de) 2009-10-15

Family

ID=34825960

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05706024T ATE445404T1 (de) 2004-01-21 2005-01-21 Verwendung von adefovir oder tenofovir zur hemmung von mmtv-artigen viren im zusammenhang mit brustkrebs und primärer biliärer zirrhose

Country Status (10)

Country Link
US (2) US20070281911A1 (https=)
EP (1) EP1732569B1 (https=)
JP (1) JP2007518815A (https=)
AT (1) ATE445404T1 (https=)
AU (1) AU2005209256B2 (https=)
CA (1) CA2553455A1 (https=)
DE (1) DE602005017131D1 (https=)
ES (1) ES2334149T3 (https=)
NZ (1) NZ548532A (https=)
WO (1) WO2005072748A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006114065A2 (en) * 2005-04-25 2006-11-02 Institute Of Organic Chemistry And Biochemistry A Cademy Of Sciences Of The Czech Republic Use of compounds to inhibit neoplasia
RU2301088C2 (ru) * 2005-09-01 2007-06-20 Ростовский научно-исследовательский онкологический институт МЗ РФ Способ лечения рецидива рака молочной железы
SI2020996T1 (sl) 2006-05-16 2012-03-30 Gilead Sciences Inc Postopek in sestavki za zdravljenje hematološkihmalignosti
WO2011044125A1 (en) * 2009-10-05 2011-04-14 Ambergen, Inc. A method for diagnosing primary biliary cirrhosis (pbc) using novel autoantigens
EP2625292B1 (en) 2010-10-07 2018-12-05 The General Hospital Corporation Biomarkers of cancer
ES3018133T3 (en) 2011-11-30 2025-05-14 Univ Emory Jak inhibitors for use in the prevention or treatment of a viral disease caused by a coronaviridae
EP3161159B1 (en) 2014-06-25 2020-08-05 The General Hospital Corporation Targeting human satellite ii (hsatii)
JP7381190B2 (ja) 2014-12-26 2023-11-15 エモリー・ユニバーシテイ N4-ヒドロキシシチジン及び誘導体並びにそれに関連する抗ウイルス用途
GB201509431D0 (en) * 2015-06-01 2015-07-15 Equigerminal Sa Antiviral composition
PT3706762T (pt) 2017-12-07 2024-12-05 Univ Emory N4-hidroxicitidina e derivados e utilizações antivirais relacionadas com os mesmos
KR102196711B1 (ko) * 2018-08-30 2020-12-30 가톨릭대학교 산학협력단 테노포비르 디소프록실 푸마르산을 유효성분으로 함유하는, 간섬유증 예방 또는 치료용 약학적 조성물
US20220143050A1 (en) * 2019-02-22 2022-05-12 Kazumoto Murata mTOR Inhibitor
WO2021003421A1 (en) * 2019-07-02 2021-01-07 Virago Vax Inc. Mammary tumor virus suppression
US12016844B2 (en) 2019-07-02 2024-06-25 Virago Vax Inc. Mammary tumor virus suppression
US12029783B2 (en) 2019-07-02 2024-07-09 Virago Vax Inc. Mammary tumor virus vaccine
IL315480A (en) 2022-03-15 2024-11-01 Rome Therapeutics Inc Compounds and methods for treating disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60038889D1 (de) * 1999-06-01 2008-06-26 Ochsner Med Found Alton Identifizierung eines neuartigen retrovirus welcher mit primärer leberzirrhose sowie autoimmunerkrankungen einhergeht
EP1190055B1 (en) * 1999-06-30 2008-06-25 The Administrators Of The Tulane Educational Fund Human endogenous retrovirus
US20020119443A1 (en) * 2000-07-21 2002-08-29 Gilead Sciences, Inc. Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same
EP2223927B1 (en) * 2002-05-13 2014-10-15 Metabasis Therapeutics, Inc. Salts of a phosphonic acid based prodrug of PMEA

Also Published As

Publication number Publication date
NZ548532A (en) 2009-09-25
EP1732569B1 (en) 2009-10-14
AU2005209256B2 (en) 2010-11-18
US20070281911A1 (en) 2007-12-06
ES2334149T3 (es) 2010-03-05
AU2005209256A1 (en) 2005-08-11
DE602005017131D1 (de) 2009-11-26
HK1099228A1 (en) 2007-08-10
US20050239753A1 (en) 2005-10-27
WO2005072748A1 (en) 2005-08-11
EP1732569A1 (en) 2006-12-20
JP2007518815A (ja) 2007-07-12
CA2553455A1 (en) 2005-08-11

Similar Documents

Publication Publication Date Title
ATE445404T1 (de) Verwendung von adefovir oder tenofovir zur hemmung von mmtv-artigen viren im zusammenhang mit brustkrebs und primärer biliärer zirrhose
PH12020551244A1 (en) Pd-1/pd-l1 inhibitors
BR112023000205A2 (pt) Misturas fungicidas
CR20190478A (es) Inhibidores de pd-1/pd-l1
CL2004002050A1 (es) Compuestos derivados de piridinonas sustituidas; su uso en el tratamiento de afecciones causadas o exacerbadas por actividad p38 map kinasa y/o tnf no regulada, tales como inflamaciones, tumores, sida y otros.
EA201000777A1 (ru) Ингибиторы репликации вируса иммунодефицита человека
ITMI20052171A1 (it) Composti e-amminocarbonil bicicloepten pirimidindiamminici stereoisomericamente arricchiti e loro uso
EA201290583A1 (ru) Противовирусная терапия
CY1108399T1 (el) Τετραϋδροπυριδοθειοφαινια
IS7997A (is) Granisetron lyfjaplástur
NO20064547L (no) Fremgangsmater for behandling av HIV infeksjon
EA202191257A1 (ru) Противораковая терапия на основе иммуноцитов, связывающих liv1
MX389999B (es) Estabilizadores de mastocitos para el tratamiento de hipercitoquinemia e infeccion viral
CO2022000481A2 (es) Inhibidores de enzimas
CY1109440T1 (el) Φωσφοϊνδολες ως αναστολεις hiv
BRPI0515319A (pt) análogos de quinolona
ATE541848T1 (de) Diaryl-purin, azapurine und deazapurine als nichtnukleoside reverse-transkriptase-inhibitoren zur behandlung von hiv
MX2022000811A (es) Inhibidores de enzimas.
ATE447960T1 (de) Antivirale verwendung von borinsäurekomplexen
ATE397000T1 (de) Tetrahydropyridothiophenen zur verwendung in der behandlung von krebs
UY29417A1 (es) Agentes endoparasiticidas
EA202091694A1 (ru) Ингибиторы pd-1/pd-l1
WO2019108004A3 (en) Therapeutic agent for blood cancer
RU2010139486A (ru) Способ коррекции гиперэстрадиолемии и нормогонадотропного гипогонадизма у мужчин
MX393648B (es) Preparaciones que tienen efectividad mejorada como retardantes de llama

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties